{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:26:22Z","timestamp":1761823582847,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.purol.2013.09.007","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T09:15:47Z","timestamp":1382346947000},"page":"1287-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Les m\u00e9dicaments de l\u2019ur\u00e8tre"],"prefix":"10.1016","volume":"23","author":[{"given":"X.","family":"Game","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-N.","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Descazeaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Droupy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Benard-Laribiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bastide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bruy\u00e9re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2013.09.007_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0094-0143(21)00501-2","article-title":"Anatomy and physiology of the lower urinary tract","volume":"20","author":"de Groat","year":"1993","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.purol.2013.09.007_bib0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgyn.2007.11.029","article-title":"[Female urinary stress incontinence: analysis of pathophysiological hypothesis]","volume":"37","author":"Deffieux","year":"2008","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1016\/j.purol.2013.09.007_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.rehab.2008.12.013","article-title":"Sacral reflexes and urinary incontinence in women: new concepts","volume":"52","author":"Deffieux","year":"2009","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0022-5347(01)65212-1","article-title":"Initiation of voiding in humans: the nature and temporal relationship of urethral sphincter responses","volume":"157","author":"Yalla","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0090-4295(01)01633-8","article-title":"Central pathways controlling micturition and urinary continence","volume":"59","author":"Blok","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000161128","article-title":"Comparison of the potency of different brands of Serenoa repens extract on 5-alpha reductase types I and II in prostatic co-cultured epithelial and fibroblast cells","volume":"82","author":"Scaglione","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.purol.2013.09.007_bib0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1248\/bpb.32.646","article-title":"Pharmacologically relevant receptor binding characteristics and 5-alpha reductase inhibitory activity of free fatty acids contained in saw palmetto extract","volume":"32","author":"Abe","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.purol.2013.09.007_bib0040","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.1111\/j.1464-410X.2012.11144.x","article-title":"Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1\/CCL2\u00a0and VCAM-1, in vitro","volume":"110","author":"Latil","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.007_bib0045","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-009-9304-y","article-title":"NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth","volume":"28","author":"Papaioannou","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.purol.2013.09.007_bib0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/aja.2011.132","article-title":"Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures","volume":"14","author":"Larre","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.purol.2013.09.007_bib0055","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/pros.21138","article-title":"Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)","volume":"70","author":"Quiles","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.purol.2013.09.007_bib0060","first-page":"CD001423","article-title":"Serenoa repens for benign prostatic hyperplasia","volume":"12","author":"Tacklind","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.007_bib0065","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.2011.1364","article-title":"Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial","volume":"306","author":"Barry","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.purol.2013.09.007_bib0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa053085","article-title":"Saw palmetto for benign prostatic hyperplasia","volume":"354","author":"Bent","year":"2006","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0302-2838(02)00066-0","article-title":"Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study","volume":"41","author":"Debruyne","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","article-title":"Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098\u00a0patients","volume":"29","author":"Carraro","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.purol.2013.09.007_bib0085","first-page":"395","article-title":"[Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]","volume":"12","author":"Glemain","year":"2002","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.purol.2013.09.007_bib0400","first-page":"CD001044","article-title":"Pygeum africanum for benign prostatic hyperplasia","author":"Wilt","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.007_bib0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","article-title":"[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]","volume":"22","author":"Descazeaud","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0022-5347(17)36170-0","article-title":"Alpha 1\u00a0adrenoceptor subtypes in the human prostate","volume":"149","author":"Lepor","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/nau.21224","article-title":"Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart","volume":"31","author":"Kojima","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2013.09.007_bib0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group","volume":"37","author":"van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","article-title":"Efficacy and safety of once daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0125","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","article-title":"A second phase III multicenter placebo-controlled study of 2\u00a0dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01\u00a0Study Group","volume":"160","author":"Narayan","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/pcan.2010.46","article-title":"Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH","volume":"14","author":"Roehrborn","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.purol.2013.09.007_bib0140","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2009.06.072","article-title":"Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study","volume":"74","author":"Marks","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.purol.2011.07.009","article-title":"Traitement m\u00e9dical de l\u2019hyperplasie b\u00e9nigne de la prostate\u00a0: revue de litt\u00e9rature par le CTMH\/AFU","volume":"22","author":"Robert","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1464-410X.2008.07458.x","article-title":"Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice","volume":"101","author":"Vallancien","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.007_bib0160","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1464-410X.2011.10233.x","article-title":"Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)","volume":"108","author":"Yu","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.007_bib0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jsm.12023","article-title":"SOP conservative (medical and mechanical) treatment of erectile dysfunction","volume":"10","author":"Porst","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0170","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ophtha.2008.12.026","article-title":"Factors associated with intraoperative floppy iris syndrome","volume":"116","author":"Neff","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.purol.2013.09.007_bib0175","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.ju.0000139539.94828.29","article-title":"Dihydrotestosterone and the prostate: the scientific rationale for 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0180","first-page":"814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.purol.2013.09.007_bib0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5-alpha reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.purol.2013.09.007_bib0190","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-5347(05)67910-4","article-title":"A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride","volume":"163","author":"Foley","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0195","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0022-5347(05)64287-5","article-title":"Transurethral prostate resection and bleeding: a randomized, placebo-controlled trial of role of finasteride for decreasing operative blood loss","volume":"168","author":"Donohue","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/00365590510007694","article-title":"Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study","volume":"39","author":"Lund","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.purol.2013.09.007_bib0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.pcan.4500818","article-title":"Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study","volume":"8","author":"Ozdal","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.purol.2013.09.007_bib0210","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrurol.2011.67","article-title":"Targeting 5-alpha reductase for prostate cancer prevention and treatment","volume":"8","author":"Nacusi","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0090-4295(99)80291-X","article-title":"Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group","volume":"46","author":"Andersen","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0220","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0090-4295(96)00353-6","article-title":"Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials","volume":"48","author":"Boyle","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0230","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0235","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(98)00094-6","article-title":"Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group","volume":"51","author":"Marberger","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0245","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0250","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two-year study","volume":"155","author":"Nickel","year":"1996","journal-title":"CMAJ"},{"key":"10.1016\/j.purol.2013.09.007_bib0255","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1\u00a0and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.007_bib0260","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2008.10.037","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0270","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0275","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"New Eng J Med"},{"key":"10.1016\/j.purol.2013.09.007_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2013.04.132","article-title":"Male breast cancer and 5-alpha reductase inhibitors, finasteride and dutasteride","author":"Bird","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0285","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","article-title":"Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0290","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0295","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","article-title":"A randomised, placebo-controlled study to assess the efficacy of twice daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"53","author":"Stief","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00365599.2012.752404","article-title":"Treatment of lower urinary tract symptoms: agents for intraprostatic injection","volume":"47","author":"Andersson","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0305","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11934-007-0035-3","article-title":"Primary bladder neck obstruction in men, women, and children","volume":"8","author":"Padmanabhan","year":"2007","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.purol.2013.09.007_bib0310","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/S0022-5347(17)32310-8","article-title":"Detrusor bladder neck dyssynergia revisited","volume":"152","author":"Schurch","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/01952307.1993.11735903","article-title":"Clinical effect of alpha-1\u00a0antagonism by terazosin on external and internal urinary sphincter function","volume":"16","author":"Chancellor","year":"1993","journal-title":"J Am Paraplegia Soc"},{"key":"10.1016\/j.purol.2013.09.007_bib0320","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0022-5347(01)67524-4","article-title":"Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?","volume":"153","author":"O\u2019Riordan","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000019818","article-title":"A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction","volume":"35","author":"Yamanishi","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0330","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"de Seze","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.purol.2013.09.007_bib0335","first-page":"470","article-title":"A UK consensus on the management of the bladder in multiple sclerosis","volume":"80","author":"Fowler","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.purol.2013.09.007_bib0340","unstructured":"Avis de la HAS pour la prise en charge \u00e0 titre d\u00e9rogatoire decertaines sp\u00e9cialit\u00e9s pharmaceutiques, produits ou prestations pr\u00e9vue \u00e0 l\u2019article L.\u00a0162-17-2-1\u00a0: alpha-bloquants. 2010."},{"key":"10.1016\/j.purol.2013.09.007_bib0345","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0350","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","article-title":"Placebo-controlled, randomised, double-blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients","volume":"76","author":"Gallien","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.purol.2013.09.007_bib0355","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00192-009-0836-7","article-title":"The facilitatory effect of duloxetine combined with pelvic floor muscle training on the excitability of urethral sphincter motor neurons","volume":"20","author":"Mehnert","year":"2009","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.purol.2013.09.007_bib0360","unstructured":"Organization EM. European public assessment report YENTREVE. In: Organization EM, editor. 2004."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.purol.2013.09.007_bib0365","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1471-0528.2006.00877.x","article-title":"What do we know about duloxetine's mode of action? Evidence from animals to humans","volume":"113","author":"Schuessler","year":"2006","journal-title":"BJOG"},{"key":"10.1016\/j.purol.2013.09.007_bib0370","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11255-013-0410-6","article-title":"The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis","volume":"45","author":"Li","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.purol.2013.09.007_bib0375","first-page":"CD004742","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults","volume":"20","author":"Mariappan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.007_bib0380","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/01.ju.0000154167.90600.c6","article-title":"A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence","volume":"173","author":"Ghoniem","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0385","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0390","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2010.10.031","article-title":"Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial","volume":"59","author":"Cornu","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.007_bib0395","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.eururo.2006.08.005","article-title":"Pharmacologic treatment in postprostatectomy stress urinary incontinence","volume":"51","author":"Filocamo","year":"2007","journal-title":"Eur Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713006933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713006933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:23:52Z","timestamp":1761114232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708713006933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":79,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1166708713006933"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.007","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les m\u00e9dicaments de l\u2019ur\u00e8tre","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}